Corticosteroids (CSs) are still the mainstay of induction, rescue, and maintenance in heart transplantation (HTx). However, their use is associated with significant and well-documented side effects usually related to the dose administered and the duration of therapy. Moreover, CSs interfere with the recipient's quality of life and with the active process of graft tolerance. Physicians have been exploring ways to avoid or reduce CSs in association with other immunosuppressive drugs, minimizing side effects and costs. The regimens are classified as steroid-free or steroid withdrawal protocols. The studies analyzed in this review come to similar conclusions as benefits and adverse consequences: steroid-free protocols should be advisable and mandatory in pediatric patients, insulin-dependent diabetes mellitus (IDDM), presence of infection, familial metabolic disorders/obesity, severe osteoporosis, and in the elderly. On the other hand, steroid withdrawal can be successfully achieved in 50-80%, with late better than early withdrawal, no increase in rejection-related mortality, no adverse impact on survival, and probably a better quality of live. Safety and efficacy can certainly be improved by an individualized approach to the transplant recipient.
lowering the single dosage of each, also allowing the reduction or suppression of steroids. Thus, physicians have been exploring ways to avoid or eliminate the need for long-term steroid treatment, thereby minimizing side effects and costs. These regimens classified as steroid-free or steroid withdrawal protocols (early within the first 3-6 months after HTx or late between 6-12 months and beyond posttransplant) have been applied in several solid organ transplantations.
In the early 1980s, the European transplant community tried to withdraw from standard immunosuppression or avoid completely the use of CSs in organ transplantation, but the results were varied and might be not applicable to the actual therapies [15, 16] . Instead, in a more recent analysis, Lerut [17] evaluated studies using more innovative drugs and concluded that results were satisfying in almost all types of solid organ transplants if steroid avoidance had been accomplished. Moreover, the same author reported that in clinical practice of liver transplantation, there was a tendency toward steroids minimization with their avoidance more favorable than their withdrawal [18] . CS minimization protocols and sparing have been applied even in kidney transplantation [19, 20] , and a meta-analysis of Knight SR et al. [21] revealed an increase in the risk of acute rejection (AR) with steroid avoidance or withdrawal protocol (RR 1.56, CI 1.31-1.87, P < 0.0001), but with no measurable effect on graft or patient survival, reporting at the same time significant benefits in cardiovascular risk profile. Steroid withdrawal in pancreas and islet transplantation, even if the success has been validated by several transplant centers, cannot currently be recommended because lacking in prospective randomized studies to verify the risk/benefit ratio [22, 23] .
The first to describe results with steroid-free immunosuppression in HTx was Yacoub et al. [24] in 1985, whereas the first experience with steroid withdrawal was reported by Pritzker et al. [25] . Moreover, this therapeutic approach was proven to be feasible also in pediatric HTx [26, 27] .
Experience with the minimization of CSs in heart transplantation is relatively poor and more heterogeneous when compared with other solid organs, and results are difficult to interpret. In fact, the clinical use of different CSs minimization protocols and different co-treatments in various clinical settings might make clinical outcomes difficult to compare. Thus, the purpose of this paper was to focus only on CSs-free and CSs-withdrawal protocols in HTx patients to evaluate the results achieved on survival, rejection and infection rate, or other drug side effects.
The role of steroids in heart transplantation
CSs immunosuppressive action is multifactorial depending on the target cell type considered and their activation state:
(i) synthesis of lipocortins which prevent arachidonic acid release from membrane-bound stores; (ii) blockade of selected elements of the signal transduction pathways that operate as a consequence of T-cell activation; (iii) inhibition of leukocyte adhesion molecule expression; and (iv) suppression of cytokine production and action [28] . To influence cellular function, CSs must enter the cell and bind to and activate intracellular receptors, named glucocorticoid receptors (GRs), type-I and type-II [29] . Type-II GRs, widely distributed in the immune system, affect all immune cells at an intermediate level in mature T and B cells and at very low level in neutrophils [30] . GRs density in peripheral T cells is a critical determinant of sensitivity, and despite the presence of functional GRs, clinical CSs resistance can arise [31] . It has been demonstrated that chronically CSs drug therapy may alter immune cell differentiation which may be of relevance in the induction of peripheral tolerance to allergenic stimuli [32] [33] [34] [35] .
The main CSs used to prevent and treat allograft rejection are prednisolone and prednisone. From a pharmacokinetic point of view, synthetic CSs present increased bioavailability, poor linkage to CS-binding globulin (CBG) and have much longer half-life than endogenous CSs (cortisol, corticosterone) [36, 37] . CSs administration to humans results in rapid but transient lymphopenia (especially T cells) [38] and in a significant reduction in eosinophil and basophil numbers, whereas vice versa neutrophil exhibits a marked increase [39] . In clinical setting, beside the well-known effect on acute rejection, CSs could impact also on coronary allograft vasculopathy (CAV), present in 90% of patients within 10 years and considered one of the major cause of late death following HTx [40] [41] [42] [43] . Etiology of CAV is mostly immunologic, but nonimmune pathways contribute to its development. Inflammatory cells and humoral injuries are present in evolving lesions [44] ; cytokines and chemokines are known to mediate local and systemic immune responses and to recruit and activate inflammatory cells. Thus, CS minimization might accelerate the course of CAV being the disease for great part immunomediated. However, Ratkovec et al. [45] demonstrated that CSs minimization does not adversely affect the prevalence or progression of CAV during the first 2 years after HTx. Moreover, while cyclosporine and tacrolimus are not effective in preventing CAV [46] , mychophenolate mofetil, sirolimus, and everolimus seem to impact on the appearance and progression of CAV, allowing a consistent reduction in CSs [47] [48] [49] .
As it has been demonstrated that cumulative CSs dose in HTx recipients has been associated with hyperlipidemia and possibly with more diabetes and hypertension, CSs withdrawal or avoidance would decrease the incidence and progression of CAV [50] .
Methods
This review is focusing on strategies to avoid CSs after HTx as a means to improve short-and long-term outcome. To analyze the impact of different CSs protocols, we searched the PubMed database up to June 2013 using the following keywords: heart transplantation, corticosteroids, steroid-free, complete steroid avoidance, steroid withdrawal, steroid minimization, and steroid side effects. Inclusion criteria specified any prospective or retrospective trial or observational study in adult and pediatric HTx recipients. This research was considering only studies that compared steroid groups (SG) versus steroid-free groups (SFG). Studies with steroid avoidance [steroid free = SF], with early steroid withdrawal (within the first 6 months) [early withdrawal in steroid, free maintenance immunosuppression = ew-SFM], and late steroid withdrawal (between 6 and 12 months and beyond post-HTx) [late withdrawal in steroid-free maintenance immunosuppression = lw-SFM] regimens, including pediatric experiences, were then analyzed separately.
Quality assessment was performed according to the Cochrane Collaboration Criteria for the evaluation of RCTs [51] and according to the GRACE principles for the evaluation of observational studies [52] . For the evaluation of RCTs, only internal validity criteria were computed for the final 10-points score (for each item, a yes/no/unclear evaluation was made; then, 1 point was assigned for each positive mark). For the evaluation of observational studies, an overall assessment was performed in accordance with GRACE principles, ranking studies as low, medium, or high quality. Considering the different quality levels, the variety in patients' characteristics, the fact that most studies had only one arm and that evaluation of the outcomes was different among studies, a meta-analysis was not attempted. Patients were divided in steroid group (SG) and steroid-free (maintenance) group (SFG). To compare the results of the studies, the following parameters were selected: graft and patient survival, rejection and infection rate, or other complications. Results of comparison among different drug therapy approaches and relative quality assessment results are reported in Tables 1-4 . Finally, authors' conclusions were compared.
Results
Twenty-one studies were finally included in the review. Beyond what is shown in the tables, other findings will be highlighted in bold. Most studies were actually well conducted, but analyses were sometimes not appropriate for the outcome or conducted "as treated", so providing the reader with only the ideal efficacy of the treatment. Moreover, in only very few studies, a multivariable modeling was applied.
Steroid-free immunosuppression
There are few data on CSs avoidance in adult HTx, three prospective [53, 54, 56] and one retrospective [55] compared HTx results in SG versus SFG (Table 1) . Only one paper was of high quality [55] , and three were of low quality [53, 54, 56] . The reported 2-year survival was excellent either in SG and SFG without any significant differences (92% and 93% in the first study, 86% and 85% in the second, respectively) [53, 54] . When evaluating prospective studies only, the incidence of acute rejection was found to be significantly higher in SFG versus SG in two studies [53, 54] and lower in one [56] . On the contrary, the overall incidence of infections was significantly higher [53] or similar [54, 56] in SG than SFG. The use of steroids was joined with increased antihypertensive drug use [54] , vice versa reduction in bone loss and better cardiac function were recorded in the SFG [56] . Overall, it can be concluded that steroids-free therapies appear to be safe because of the good survival even in the presence of a higher rejection rate, with the incidence of infections being similar.
In the only retrospective study, rated as "high quality", dealing with 112 consecutive HTx patients initially immunosuppressed with CsA+AZA without CSs, Livi et al. [55] recorded good survival of discharged patients at 1 year and 2 years (95% and 94%, respectively), high incidence of acute rejection, and lower trend in hypertension incidence. The authors concluded that despite the more frequent occurrence of acute rejection, the excellent mid-term survival and the initial low incidence of both infection and chronic rejection justified a wider use of such treatment.
Beyond our primary end points, there are other aspects worthy to be considered. In a randomized prospective trial, Jones et al. compared the quality of life after HTx in patients treated with CsA+AZA (double therapy) versus CsA+AZA+CSs (triple therapy). Patients who received double therapy showed advantages in 10 of 11 measures of life quality with significant differences in score of anxiety, sexual activity, and physical well-being. Furthermore, patients who received double therapy reported a lower frequency of and less distress from the immunosuppression side effects with return to full-time employment and better weight control [57] .
Steroid withdrawal immunosuppression
Experience with SFM protocol is large and highly variable depending on the dose, on the duration of CSs therapy, and on the other immunosuppressive drugs used. Based on this, it is not easy to compare different studies and clinical outcomes. In different publications, we found several protocols which can be simplified in early withdrawal (ew) and late withdrawal (lw) CSs protocols. The ew-CSs protocol was reported in one prospective [25] and two retrospective trials [58, 59] (Table 2 ). All these studies were classified as high quality. The long-term survival in SFM group was significantly higher than SG in all the studies analyzed [25, 58, 59] .
Comparing the groups about rejection episodes, results appear even more controversial. In fact, while some authors agreed that SG experienced better freedom from rejection (P < 0.01) [59] , others showed that the ew-CSs protocols were associated with a lower incidence of rejection (P = 0.0002) in one study [58] or with similar results (P = 0.910) in the other [25] .
Considering the incidence of infections, Pritzker et al. [25] reported similar infective complication rates in both the groups (P = 0.091), whereas Taylor et al. revealed that treated infections were more common in patients in whom early CS weaning failed [58] . Similarly, Rosenbaum et al. [59] observed that freedom from infections did not differ between the two groups considered (P = 0.10). Moreover, the same authors observed better overall freedom from malignancy in SFM group (skin cancer, P < 0.01), while post-transplant morbidities (renal dysfunction, obesity, diabetes, CAV) were similar in both the groups. Also, Taylor observed that CAV was apparently lower in the SFM group, albeit not significant, (P = 0.10), and in other studies, SFM protocol seemed to be associated with lower lipid values, less hypertension, and better or similar weight control [25, 59] .
The lw-CSs protocol was reported in 10 papers, four prospective trials [61, 64, 65, 69] , and six retrospective [60, 62, 63, [66] [67] [68] (Table 3) . Five studies were of high quality and five of medium quality. Of the four prospective studies, only one was rated as "high quality" [64] ; Opelz et al. [65] focused on mortality reporting 7-year survival rate significantly higher in SFM group (P = 0.0008). Rejection rate was similar in both the groups according to Delgado (P = 0.825) [61] and Opelz (P = 0.148) [65] , whereas Mehra reported lower rate in SFM compared with SG (P = 0.04) [64] . The incidence of severe infections was similar in both the groups [61] or significantly more frequent in SG compared with SFM (P < 0.001) [64] . SFM groups experienced lower level of total cholesterol (P = 0.008) and a trend toward lower rate of hypertension [65] .
In retrospective studies, the reported survival rates were higher according to Felkel (5 years: 93% in SFM group versus 77% in SG (P < 0.0001) [63] , whereas it was similar between the two groups as reported by Teuteberg and Delgado (P = 0.53, P = 0.34, respectively) [66, 67] , and it was not analyzed by Crespo Leiro [68] . Episodes of rejection at 12 and 24 months were reported to be similar in both the groups [60, 65, 66] , lower in the SFM group (P < 0.0001) [63] , or not analyzed [67] [68] [69] , as well as the incidence of infections [60] or other complications [61, 68] . Summarizing the authors' conclusions, the use of CSs for more than 1 year after transplantation seems unlikely to provide clinical benefit [61] ; moreover, in SFM group, good long-term outcomes and no worsening of allograft function were observed [65] , with a trend toward reduction in rejection incidence, number of infection episodes [60] , and hypertension rate [68] .
Pediatric experiences
There are four studies on pediatric experiences, one prospective [70] and three retrospectives [26, 71, 72] (Table 4) . Three studies were classified as high quality [70] [71] [72] , and only one was of medium quality [26] . Two retrospective publications on steroid-free protocols come to similar conclusions [26, 72] . Livi et al. [26] reported their experience on 30 pediatric HTx patients receiving CsA/AZA alone, observing 1-, 5-, and 10-year overall patient survival at 80%, 76%, and 76%, respectively, a rejection rate of 1.2 episodes per patient, and an infection frequency of 0.2 episodes per patient. Singh et al. [72] reported the outcome of 55 HTx pediatric recipients with a post-transplant survival of 91% at 6 months and 88% at 12 and 24 months, whereas freedom from first rejection was still over 80% at 2 years.
Two publications reported early and late steroid withdrawal. Canter et al. [70] prospectively evaluated the feasibility of steroids withdrawing at 6 to 12 months after HTx in 21 pediatric patients. Four of 21 patients (24%) had rejection after steroid withdrawal, and survival rate was 88% at 6 months. Similar results were obtained in a retrospective study by Leonard et al. [71] who reported in 77 HTx pediatric patients a survival of 88, 85, and 70% at 1, 5, and 10years, respectively, with an overall rejection rate of 0.03 episodes/patient/year. The author concluded that this regimen presented a very good rejection-free survival.
In conclusion, experience in pediatric HTx has been shown in many centers to have excellent outcomes by complete steroid avoidance. Thus today, the "one size fits all" approach to immunosuppressive therapy in pediatric patients is an obsolete concept, and the ultimate target should be to tailor immunosuppression for any single case [73] .
Limitations
Despite the application of the Cochrane and GRACE criteria, the real quality of studies was sometimes difficult to evaluate. Most studies were retrospectives, and their design or analysis seems to be not always appropriate to evaluate outcomes, and moreover, those have been conducted "as treated" demonstrating only the feasibility and the efficacy of the new therapy. This means that in most cases, where SG was compared with SF/SFM groups, the SFG/SFM was defined as group of patients in whom steroid avoidance or withdrawal was finally achieved. Also, multivariable modeling was applied only in few studies and so probably a immunologically privileged group in which steroids could be effectively withdrawn was compared to the rest of the study group.
Conclusions
Many of the cited studies showing good results of steroid weaning were those where steroid withdrawal was attempted in all patients, and then, 30-50% of weaned patients were compared with the patient cohort in which weaning was not successful. The conclusion coming from different studies that steroid weaning could be advantageous is a leap of faith as usually two different patient populations were compared. For example, the Yamani study [56] included only patients that were thought to be immunologically at low risk (PRA < 10%, virtual and actual cross-match negative). In addition to all the studies reported in this review, other trials, not focusing specifically on steroids, provide important information about efficacy of steroid withdrawal. For instance, in the TICTAC study where steroids were discontinued after 8 weeks in all patients (150 patients), the long-term outcome was excellent [74] .
In recent guidelines reported by the International Society of Heart and Lung Transplantation (ISHLT) [75] , CS avoidance, early CS weaning, or very low-dose maintenance CS therapy are all acceptable therapeutic approaches with level of evidence B. In the present review, the studies analyzed came overall to similar conclusions in terms of benefits and adverse consequences of both CS-free and CSwithdrawal protocols after HTx: 1) good mid-and longterm graft/patient survival; 2) higher incidence of acute rejection in CS-free approach; 3) a variable incidence of infection episodes; 4) lower serum cholesterol levels; 5) possibly lower hypertension rate; 6) amelioration of weight control; and 7) slightly lower risk of diabetes and bone loss. Accordingly, CS-free therapy should be advisable and sometimes mandatory in pediatric age, in cases of active infection, IDDM, familial metabolic disorders/obesity, severe osteoporosis, and in elderly patients. In all HTx patients, CS withdrawal seems to be feasible (any age, sex, and race; at present, a success rate of 50-80%) and safe (does not increase rejection-related mortality and has no adverse impact on survival) and maybe more practicable when combined with the new drugs. Defining what is better, whether early or late withdrawal, does not seem currently possible because the number of published trials is still limited. Anyhow, early steroid withdrawal should be used in recipients with a lower propensity to rejection, also in the long term.
The very critical aspect is that many of the cited studies were reporting a successful attempt of steroid withdrawal in more than 50% of patients treated and those compared with patients in which steroids weaning was not successfully achieved. This incorrect methodology can favor erroneous interpretation of the results, as the feasibility and efficacy of steroids avoidance or withdrawal reflect probably an immune-privileged subset of patients.
In conclusion, a prospective randomized trial should be carried out to verify whether CS withdrawal or CS-free maintenance improve long-term outcome following HTx and impact significantly on quality of life by reducing complications and immunosuppression side effects.
